A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Sponsor
Hoffmann-La Roche
Study ID
NCT01144364
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
60 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

Key Dates

Start date
Jan 19, 2004
Status verified
Jun 2017
Primary completion
Jul 21, 2011
Completion
Jul 21, 2011

Study Design

Enrollment
234 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Percentage of Participants With Disease Progression or Death [ Time Frame: 12, 24, and 34 months ]

Related Studies